HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line
- Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
- Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
- The overexpression lentivector is also available as plasmid and pre-packaged virus
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CVD19-220A-1 | HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line | 2 x 10^6 Cells | $3499 |
|
||||
Overview
Overview
Advance your COVID-19 studies with SBI
Explore interactions of the SARS-CoV-2 nucleocapsid protein with host proteins and more using the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. Built using our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, this stable cell line overexpresses the SARS-CoV-2 "N" protein—the nucleocapsid—from the CMV promoter, with a separate EF1α promoter driving expression of the puromycin resistance gene for selection.- Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
- Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
- The overexpression lentivector is also available as plasmid and pre-packaged virus
See all of our COVID-19-related Expression Constructs
| Catalog Number | Product name |
|---|---|
| CVD19-100PA/VA-1 | ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-140PA/VA-1 | NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus) |
| CVD19-120PA/VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-130PA/VA-1 | SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-135PA/VA-1 | SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-200A-1 | HEK293 ACE2 Stable Cell Line |
| CVD19-260A-1 | HEK293-ACE2-NRP1 Overexpression Stable Cell Line |
| CVD19-220A-1 | HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line |
| CVD19-420A-1 CVD19-425A-1 | "N" SARS-CoV-2 Nucleocapsid mRNA |
| CVD19-430A-1 CVD19-435A-1 | "S" SARS-CoV-2 Spike Glycoprotein mRNA |
| CVD19-440A-1 CVD19-445A-1 | "S" SARS-CoV-2 Spike Omicron mRNA |
References
How It Works
Supporting Data
Supporting Data
Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. We transduced the SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, we extracted total protein and analyzed nucleocapsid protein expression via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.
FAQs
Resources
Citations
Related Products
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CVD19-220A-1 | HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line | 2 x 10^6 Cells | $3499 |
|
||||
Overview
Overview
Advance your COVID-19 studies with SBI
Explore interactions of the SARS-CoV-2 nucleocapsid protein with host proteins and more using the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. Built using our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, this stable cell line overexpresses the SARS-CoV-2 "N" protein—the nucleocapsid—from the CMV promoter, with a separate EF1α promoter driving expression of the puromycin resistance gene for selection.- Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
- Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
- The overexpression lentivector is also available as plasmid and pre-packaged virus
See all of our COVID-19-related Expression Constructs
| Catalog Number | Product name |
|---|---|
| CVD19-100PA/VA-1 | ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-140PA/VA-1 | NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus) |
| CVD19-120PA/VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-130PA/VA-1 | SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-135PA/VA-1 | SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
| CVD19-200A-1 | HEK293 ACE2 Stable Cell Line |
| CVD19-260A-1 | HEK293-ACE2-NRP1 Overexpression Stable Cell Line |
| CVD19-220A-1 | HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line |
| CVD19-420A-1 CVD19-425A-1 | "N" SARS-CoV-2 Nucleocapsid mRNA |
| CVD19-430A-1 CVD19-435A-1 | "S" SARS-CoV-2 Spike Glycoprotein mRNA |
| CVD19-440A-1 CVD19-445A-1 | "S" SARS-CoV-2 Spike Omicron mRNA |
References
How It Works
Supporting Data
Supporting Data
Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. We transduced the SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, we extracted total protein and analyzed nucleocapsid protein expression via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.